Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
09:00am, Sunday, 31'st May 2026
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
09:00am, Saturday, 30'th May 2026
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNAÂ (talazoparib), an oral poly ADP-ri
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
06:01pm, Thursday, 07'th May 2026
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Famil
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics
05:00pm, Thursday, 07'th May 2026
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
04:26pm, Thursday, 07'th May 2026
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.74 per share
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CZNL, HLX, APLS, and SLNO
11:09am, Tuesday, 05'th May 2026
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders a
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
11:21am, Wednesday, 29'th Apr 2026
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Are CCO, EHAB, APLS, VRE Obtaining Fair Deals for their Shareholders?
06:59pm, Monday, 20'th Apr 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS
11:01am, Tuesday, 14'th Apr 2026
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders a
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
01:34pm, Friday, 10'th Apr 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of “Hold” by Analysts
03:18am, Friday, 10'th Apr 2026
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) have received an average recommendation of "Hold" from the twenty-three brokerages that are currently covering the firm, Market
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
07:33am, Tuesday, 07'th Apr 2026
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transactio
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get
06:40am, Monday, 06'th Apr 2026
Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.
Pre-Market Stock Futures: Risk-on appeared back, at least for the last two days, as the stock market put together another rally on Wednesday, with hopes for an end to the war in Iran and some solid ec
